Titlebook: Cell and Gene Therapies; Miguel-Angel Perales,Syed A. Abutalib,Catherine Bo Book 2019 Springer Nature Switzerland AG 2019 Chimeric antigen

鳥場

書目名稱Cell and Gene Therapies影響因子(影響力)




書目名稱Cell and Gene Therapies影響因子(影響力)學科排名




書目名稱Cell and Gene Therapies網(wǎng)絡(luò)公開度




書目名稱Cell and Gene Therapies網(wǎng)絡(luò)公開度學科排名




書目名稱Cell and Gene Therapies被引頻次




書目名稱Cell and Gene Therapies被引頻次學科排名




書目名稱Cell and Gene Therapies年度引用




書目名稱Cell and Gene Therapies年度引用學科排名




書目名稱Cell and Gene Therapies讀者反饋




書目名稱Cell and Gene Therapies讀者反饋學科排名

灌溉

障礙

Chimeric Antigen Receptor T Cells: Antigen Selection, CAR Development, and Data in Neoplastic Hematogen receptor T cells provide exciting potential for curative treatments to patients with cancers found intractable with current therapies. Toxicities are one of the main limiting factors for wide applicability of CAR-T-cell therapy. The major limiting adverse events include neurotoxicity and cytokin

aneurysm

Chimeric Antigen Receptor T Cells for Leukemias in Children: Methods, Data, and Challengesacute lymphoblastic leukemia (ALL) and 50–60% with acute myeloid leukemia (AML) experience long-term disease control after multimodal treatments that often include intensified chemotherapy. Relapsed leukemia patients pose a challenging subset of the pediatric leukemic population due to highly resist

Interim

制定法律

Chimeric Antigen Receptor T Cells for Lymphomas: Methods, Data, and Challengesll lymphocytic lymphoma (CLL/SLL) and B-cell acute lymphoblastic leukemia (B-ALL). However, targeting CD19 can result in prolonged B-cell aplasia. Given the clinical experience with the anti-CD20 monoclonal antibody rituximab with temporary B-cell aplasia, severe clinical consequence has not been ob

制定法律

T Cell Receptors-Gene-Modified T Cells for Cancer: Methods, Data, and Challengeslogy and new developments in synthetic biology have led to an ability to engineer T cells to express antibody-like recognition molecules linked to T cell-activating domains (chimeric antigen receptors, CARs) and tumor-specific T cell receptors (TCRs) which redirect patient-derived T cells toward the

有說服力

吹牛大王

cogent

Natural Killer Cells: What Have We Learned?of the potential of immunotherapy as a therapeutic strategy. In recent years, such skepticism has diminished significantly as clinical evidence increasingly demonstrates the effectiveness of manipulating the immune system to treat a variety of established tumors. Among components of the immune syste